Determinants of asthma after severe respiratory syncytial virus bronchiolitis Leonard B. Bacharier, MD, Rebecca Cohen, MD, Toni Schweiger, RN, Huiquing Yin-DeClue, PhD, Chandrika Christie, MA, Jie Zheng, MS, Kenneth B. Schechtman, PhD, Robert C. Strunk, MD, Mario Castro, MD, MPH Journal of Allergy and Clinical Immunology Volume 130, Issue 1, Pages 91-100.e3 (July 2012) DOI: 10.1016/j.jaci.2012.02.010 Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Enrollment and follow-up of participants through the RBEL study. Patients were enrolled during an episode of severe RSV bronchiolitis and followed prospectively through the first 6 years of life. GE, Gastroesophageal. Journal of Allergy and Clinical Immunology 2012 130, 91-100.e3DOI: (10.1016/j.jaci.2012.02.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Survival curves for time to development of the first 3 wheezing illnesses and physician’s diagnosis of asthma subsequent to the index RSV bronchiolitis episode. The vertical axis represents the probability of not wheezing (for times to first, second, and third wheezing episodes) or not having physician-diagnosed asthma (blue circles). Blue triangles represent the first subsequent parent-reported wheezing episode, brown triangles represent the second subsequent parent-reported wheezing episode, green triangles represent the third subsequent parent-reported wheezing episode, and blue circles represent a physician’s diagnosis of asthma. Journal of Allergy and Clinical Immunology 2012 130, 91-100.e3DOI: (10.1016/j.jaci.2012.02.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 3 ROC curves for a post-RSV Asthma Predictive Index for physician-diagnosed asthma and active asthma. A, The model for physician-diagnosed asthma, incorporating the clinically derived predictors that were significant in the univariate analyses. B, The model for physician-diagnosed asthma (red) and active asthma (blue) incorporating nasal CCL5 levels alone at enrollment. Journal of Allergy and Clinical Immunology 2012 130, 91-100.e3DOI: (10.1016/j.jaci.2012.02.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions